Get started
Author

Christoph A. Schatz

Observed names: C Schatz, Christoph A Schatz, Christoph Schatz, Schatz, Christoph
Institution: Bayer (Germany)
Observed institutions: Asan Medical Center, University of Ulsan, Stanford Health Care, Piramal (Germany), National Cancer Centre Singapore, Stanford Medicine, Bayer (Germany), Stanford University
ORCID: 0000-0001-8028-2631
Observed ORCID: 0000-0001-8028-2631
OpenAlex ID: A5017327688
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
2013 · Ningshu Liu, Bruce R. Rowley, et al. · Molecular Cancer Therapeutics · 266
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2014 · Sven Golfier, Charlotte Kopitz, et al. · Molecular Cancer Therapeutics · 254
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2019 · Antje M. Wengner, Gerhard Siemeister, et al. · Molecular Cancer Therapeutics · 213
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2012 · Gerhard Siemeister, Ulrich Lücking, et al. · Molecular Cancer Therapeutics · 161
Exploratory Clinical Trial of (4 S )-4-(3-[18F]fluoropropyl)- l -glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
2012 · Sora Baek, Chang-Min Choi, et al. · Clinical Cancer Research · 132
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
2019 · Urs B. Hagemann, Christine Ellingsen, et al. · Clinical Cancer Research · 117
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
2020 · Ulrich Lücking, Lars Wortmann, et al. · Journal of Medicinal Chemistry · 86
Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
2016 · Anette Sommer, Charlotte Kopitz, et al. · Cancer Research · 76
Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
2011 · Heike M. Petrul, Christoph A. Schatz, et al. · Molecular Cancer Therapeutics · 68
(4S)-4-(3-18F-Fluoropropyl)-l-Glutamate for Imaging of xC¯ Transporter Activity in Hepatocellular Carcinoma Using PET: Preclinical and Exploratory Clinical Studies
2012 · Sora Baek, Andre Mueller, et al. · Journal of Nuclear Medicine · 67
PDF
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
2021 · Pascale Lejeune, Véronique Cruciani, et al. · Journal for ImmunoTherapy of Cancer · 60
PDF
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
2018 · Maria Quanz, Urs B. Hagemann, et al. · Oncotarget · 57
Targeted thorium-227 conjugates as treatment options in oncology
2023 · Jenny Karlsson, Christoph A. Schatz, et al. · Frontiers in Medicine · 34
PDF
Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA
2012 · Tobias M. Gorges, Johanna Schiller, et al. · Biomarkers · 30
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
2021 · Stefanie Hammer, Andreas Schlicker, et al. · Clinical Cancer Research · 29
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024 · Christoph A. Schatz, Sabine Zitzmann-Kolbe, et al. · Clinical Cancer Research · 27
PDF
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
2021 · Markus Berger, Lars Wortmann, et al. · Journal of Medicinal Chemistry · 23
PDF
DNA repair inhibitors sensitize cells differently to high and low LET radiation
2021 · Kristina Bannik, Balázs Madas, et al. · Scientific Reports · 20
PDF
In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
2017 · Yasutoshi Kuboki, Christoph A. Schatz, et al. · Gastric Cancer · 20
PDF
Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models
2017 · Ulrich T. Luecking, Julien Lefranc, et al. · Cancer Research · 13
Abstract 5859: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in preclinical models of trastuzumab and T-DM1 resistance
2017 · Jenny Karlsson, Urs B. Hagemann, et al. · Cancer Research · 11
Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models
2017 · Antje Margret Wengner, Gerhard Siemeister, et al. · Cancer Research · 11
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor
2024 · Antonius ter Laak, Roman C. Hillig, et al. · Journal of Medicinal Chemistry · 10
PDF
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
2023 · Jenny Karlsson, Urs B. Hagemann, et al. · Cancers · 10
PDF
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
2023 · Mari I. Suominen, Matias Knuuttila, et al. · International Journal of Molecular Sciences · 9
PDF
Works count: 155
Citation count: 1,880
H-index: 19
I10-index: 24
Year
Topic
Type